Silo Pharma (NASDAQ:SILO – Get Free Report) and Scienture (NASDAQ:SCNX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Silo Pharma and Scienture, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Scienture | 1 | 1 | 1 | 0 | 2.00 |
Scienture has a consensus target price of $37.50, indicating a potential upside of 871.50%. Given Scienture’s stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than Silo Pharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Scienture | N/A | -53.51% | -42.47% |
Earnings and Valuation
This table compares Silo Pharma and Scienture”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 32.94 | -$4.23 million | ($4.36) | -0.33 |
| Scienture | $430,000.00 | 14.72 | -$41.51 million | ($2.10) | -1.84 |
Silo Pharma has higher earnings, but lower revenue than Scienture. Scienture is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 19.5% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Silo Pharma has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500.
Summary
Scienture beats Silo Pharma on 12 of the 14 factors compared between the two stocks.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
